🔗 Share this article

While America continues making sweeping changes to its immunization schedules, an unexpected name appears somewhat surprisingly: Tracy Beth Høeg, an American of Danish descent physician and epidemiologist who initially gained attention by casting doubt on COVID-19 vaccines throughout the pandemic and has concentrated on potential deaths after COVID-19 vaccination in her short tenure at the Food and Drug Administration.

Planned Shifts to Pediatric Immunization Program

Health officials planned to reveal sweeping changes to the childhood immunization program in December, aligning the US with Denmark’s immunization schedule, sources say – a substantial departure that would place the US out of step with a large portion of the world with insufficient data for improved outcomes. This reveal has been postponed until the next year.

Rather than the director of the vaccine center, Tracy Beth Høeg is set to speak at the meeting. She was recently named acting director of the FDA’s CDER, the fifth appointee to head the center this calendar year.

Consolidating Power at the Agency

Høeg's temporary position might represent a closer partnership between the drug and vaccine centers as Høeg and Prasad solidify control at the regulatory agency – and it suggests a increased emphasis upon rolling back previously authorized immunizations at the FDA.

The new acting director has repeatedly called for ending specific childhood shot schedules in the US so as to align more like Denmark's approach, a society with universal health coverage and a citizenry about the size of Wisconsin’s.

To date public appearances, she has persisted in emphasizing on vaccines – typically the purview of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of pharmaceutical oversight.

Concerns Over Expertise

Dr. Høeg has little discernible background in medication creation, oversight or administrative roles, which has been typical for former leaders of the biologics center. She has been employed at the FDA as a key advisor to the FDA chief and CBER since spring.

“She doesn’t seem to have any of the qualifications” for leading the pharmaceutical oversight division, said Jonathan Howard. “She’s never run a scientific study. She lacks experience in leading a major agency. She lacks background in pharmaceutical oversight.”

Previous commissioners of the center would “grasp laws and regulations and the research of pharmaceutical innovation”, commented Dr. Janet Woodcock. “Objectively, she has not acquired the sort of resume that former directors who led CBER have had.”

The drug center has an immense workload at the agency, she pointed out.

“Many people just focuses on the innovative therapies, but the generic drug division clears numerous generic drugs. There is also a biosimilars division, OTC medication office and so forth, and every single one need to be looked after,” Dr. Woodcock explained. “The thing you overlook, that’s the thing that I always told people is going to bite you.”

There is also, a significant administrative element to the role, which manages over 5,000 staff members. “It’s a enormous administrative position, if you execute it properly,” she said.

Agency Reaction and Controversial Policies

Regarding questions about Høeg’s qualifications and whether this assignment indicates more teamwork among agency officials on immunizations, a press secretary said that the “inquiries are based on flawed presumptions”.

“Her resume aligns with the responsibilities of her role,” the representative stated, pointing to the time Høeg spent guiding the FDA commissioner on “drug safety and regulatory science, including predictive safety algorithms and immunization monitoring”.

In her interim role, Dr. Høeg assumes responsibility for the agency head's controversial priority voucher program, a controversial one-day therapy clearance system that allegedly concerned her predecessors. “How are these medications being selected for this expedited pathway? Who takes the decisions?” Howard questioned. “There’s a lot of lack of transparency going on at the FDA right now.”

In general, he remarked, “the FDA looks to be trending towards laxer rules of pharmaceuticals, aside from immunizations.”

Documented Track Record on Immunizations

With vaccines, Dr. Høeg has a clearer, if troubling, past, critics have noted. She authored a study using unverified volunteer-provided data to estimate the rate of myocarditis following COVID-19 immunization. She advised the Florida surgeon general Joseph Ladapo, who allegedly have changed statistics to suggest Covid vaccines are pose a greater threat than they are.

Among her “desired changes” for the current administration encompassed altering guidelines for recently developed shots and ending “unnecessary” vaccines, she said after the election on a online show. At the agency, Høeg has reportedly proposed preventing teenage boys from obtaining COVID-19 vaccinations.

“She’s an complete dogmatist who begins with her conclusions and works backwards to retrofit the evidence in a very misleading, dishonest fashion,” Howard argued.

Gaining Influence and a “Push for Payback”

Høeg became part of fellow dissenters, {like|